Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis
Authors:
- 31 May 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 28 (8) , 726-730
Abstract
Purpose: Psoriasis patients have high risk of atherosclerosis, characterized by endothelial dysfunction. We aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-α therapy. Also, to evaluate the relationship of metabolic syndrome features with these biomarkers and the effect of anti-TNF-α therapy on these molecules. Methods: Twenty-nine consecutive non-diabetic patients with moderate-to-severe psoriasis who underwent 6 months of anti-TNF-α-adalimumab therapy were studied. Metabolic and clinical evaluation was performed prior to anti-TNF-α treatment (time 0) and 6 months later. MCP-1, sE-selectin and sP-selectin serum levels were determined by ELISA. Results: Dyslipidemic and obese patients showed higher MCP-1 levels at month 6 from the onset of anti-TNF-α therapy (p = .05 and .01, respectively). sE-selectin positively correlated with pro-inflammatory molecules such as asymmetric dimethylarginine, sP-selectin and resistin at baseline and month 6 (p < .05). sE-selectin levels significantly reduced after 6 months of therapy (p = .0006). Conclusions: Metabolic syndrome features are associated with endothelial activation in patients with moderate-to-severe psoriasis. Adalimumab therapy led to a reduction in sE-selectin levels, supporting the beneficial effect of anti-TNF-α therapy on mechanisms associated with the development of atherosclerosis in psoriasis.Keywords
Funding Information
- AbbVie Inc
- Instituto de Salud Carlos III (CD15/00095)
- ISCIII (CP16/00033)
- ISCIII (RD12/0009/0013, RD16/0012/0009)
This publication has 23 references indexed in Scilit:
- Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte AdhesionPLOS ONE, 2016
- Anti‐tumor necrosis factor‐alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6‐month prospective studyThe Journal of Dermatology, 2016
- Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapyThe Journal of Dermatology, 2015
- Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patientsRheumatology International, 2015
- Anti‐TNF‐α therapy improves insulin sensitivity in non‐diabetic patients with psoriasis: a 6‐month prospective studyJournal of the European Academy of Dermatology and Venereology, 2014
- Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk FactorsThe American Journal of Medicine, 2014
- Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot studyJournal of the American Academy of Dermatology, 2013
- Platelet activation: a link between psoriasisper seand subclinical atherosclerosis - a case-control studyBritish Journal of Dermatology, 2013
- Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular DiseaseInternational Journal of Medical Sciences, 2010
- TNFα therapy in psoriatic arthritis and psoriasisAnnals of the Rheumatic Diseases, 2004